Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24083265 | 0.86 | — | — | |
| SCHEMBL5496326 | 0.80 | KDM4E (0.50) | KDM4ESMN1; SMN2ALDH1A1KEAP1CYP1A2 | |
| SCHEMBL235080 | 0.79 | KDM4E (0.65) | KDM4ESMN1; SMN2ALDH1A1KEAP1GLA | |
| SCHEMBL20329460 | 0.76 | SMN1; SMN2 (0.46) | KDM4ESMN1; SMN2ALDH1A1KEAP1CYP1A2 | |
| SCHEMBL10501656 | 0.76 | KEAP1 (0.52) | KDM4ESMN1; SMN2ALDH1A1KEAP1CYP1A2 | |
| SCHEMBL18434868 | 0.76 | KDM4E (0.46) | KDM4ESMN1; SMN2ALDH1A1KEAP1CYP1A2 | |
| SCHEMBL674062 | 0.76 | ALDH1A1 (0.52) | KDM4ESMN1; SMN2ALDH1A1KEAP1CYP1A2 | |
| SCHEMBL6044315 | 0.76 | GLA (0.47) | KDM4ESMN1; SMN2ALDH1A1KEAP1CYP1A2 | |
| SCHEMBL10913328 | 0.76 | KDM4E (0.70) | KDM4ESMN1; SMN2ALDH1A1KEAP1GLA | |
| SCHEMBL11856358 | 0.76 | KDM4E (0.70) | KDM4ESMN1; SMN2ALDH1A1KEAP1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3150589-A1 | IRE-1A INHIBITORS | MannKind Corporation (US) | 2017-04-05 | — | — | EP | disclosed |
| US-8912216-B2 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20140038960-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-7566734-B2 | Imidazolyl derivatives | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2009-07-28 | — | — | US | disclosed |
| US-20070299073-A1 | Imidazolyl derivatives | IPSEN PHARMA S.A.S. (FR) | 2007-12-27 | — | — | US | disclosed |
| US-20070270412-A1 | NOVEL PHARMACEUTICALS | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
| US-7262192-B2 | Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors | PFIZER INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7238695-B2 | Imidazolyl derivatives | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, SAS (FR) | 2007-07-03 | — | — | US | disclosed |
| WO-2007071455-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES , THEIR PREPARATION AND USE AS DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-06-28 | — | — | WO | disclosed |
| US-7220765-B2 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (SCRAS) (FR) | 2007-05-22 | — | — | US | disclosed |
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2007-02-08 | — | — | US | disclosed |
| US-7109186-B2 | 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004004657-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | KDM4E 702/4885SMN1; SMN2 4612/4885ALDH1A1 563/4885 |
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | KDM4E 3467/4885SMN1; SMN2 4263/4885ALDH1A1 2005/4885 |
| US-20070299073-A1 | Imidazolyl derivatives | SSTR5, SSTR3, SSTR2 | KDM4E 3035/4885SMN1; SMN2 3365/4885ALDH1A1 2490/4885 |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | GHSR, IGF1R, GIPR | KDM4E 4639/4885SMN1; SMN2 1272/4885ALDH1A1 4368/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | KDM4E 2465/4885SMN1; SMN2 3014/4885ALDH1A1 1380/4885 |
| US-20140038960-A1 | Hetaryl-[1,8]naphthyridine derivatives | ATP5F1A, ATP5ME, ATP5F1D | KDM4E 3624/4885SMN1; SMN2 4421/4885ALDH1A1 1429/4885 |
| US-20070270412-A1 | NOVEL PHARMACEUTICALS | ABCB11, PCSK9, SLC10A1 | KDM4E 3392/4885SMN1; SMN2 2626/4885ALDH1A1 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.